ESR1 and breast carcinoma: For instance, given the KAT6A amplification in 10-15% of breast cancers, novel compounds against KAT6A/KAT68 (PF-9363) have been developed and analyses in preclinical models demonstrate potent anti-tumor activity in ER+ breast cancer cells and xenografts with KAT6A dysregulation (93).